Mermelstein; Fred H.

Patent Applications and Registrations

Patent applications and USPTO patent grants for Mermelstein; Fred H..The latest application filed is for "nmda receptor antagonist formulation with reduced neurotoxicity".

Company Profile

0.12.25

Mermelstein; Fred H. - Upper Montclair NJ
Mermelstein; Fred H. - West Newton MA
Mermelstein; Fred H. - Newton MA
Mermelstein; Fred H. - Newtown MA US
Mermelstein; Fred H. - Clifton NJ

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Nmda Receptor Antagonist Formulation With Reduced Neurotoxicity App 20220054435 - Mermelstein; Fred H. ; et al.	2022-02-24
Method of treating atrophic vaginitis Grant 9,693,953 - Chollet , et al. July 4, 2	2017-07-04
Compositions and methods for topical tamoxifen citrate therapy Grant 9,480,662 - Chollet , et al. November 1, 2	2016-11-01
Nmda Receptor Antagonist Formulation With Reduced Neurotoxicity App 20160175266 - Mermelstein; Fred H. ; et al.	2016-06-23
Nmda Receptor Antagonist Formulation With Reduced Neurotoxicity App 20160000733 - Mermelstein; Fred H. ; et al.	2016-01-07
Formulations Of Low Dose Diclofenac And Beta-cyclodextrin App 20150105467 - Wright; Curtis ; et al.	2015-04-16
Formulations of low dose diclofenac and beta-cyclodextrin Grant 8,946,292 - Wright , et al. February 3, 2	2015-02-03
Nmda Receptor Antagonist Formulation With Reduced Neurotoxicity App 20140171514 - Mermelstein; Fred H. ; et al.	2014-06-19
Formulations Of Low Dose Diclofenac And Beta-cyclodextrin App 20140107209 - Wright; Curtis ; et al.	2014-04-17
Formulations of low dose diclofenac and beta-cyclodextrin Grant 8,580,954 - Wright , et al. November 12, 2	2013-11-12
Formulations Of Low Dose Diclofenac And Beta-cyclodextrin App 20110218247 - Wright; Curtis ; et al.	2011-09-08
Controlled Release Formulations App 20080221144 - Moshman; Michael ; et al.	2008-09-11
NMDA Receptor Antagonist Formulation With Reduced Neurotoxicity App 20080041367 - Mermelstein; Fred H. ; et al.	2008-02-21
Method Of Treating Atrophic Vaginitis App 20080026035 - Chollet; Janet A. ; et al.	2008-01-31
Method Of Treating Atrophic Vaginitis App 20070264309 - Chollet; Janet A. ; et al.	2007-11-15
Formulations Of Low Dose Diclofenac And Beta-Cyclodextrin App 20070232566 - Wright; Curtis ; et al.	2007-10-04
Formulations Of Low Dose Non-Steroidal Anti-Inflammatory Drugs And Beta-Cyclodextrin App 20070232567 - Wright; Curtis ; et al.	2007-10-04
NMDA receptor antagonist formulation with reduced neurotoxicity Grant 7,273,889 - Mermelstein , et al. September 25, 2	2007-09-25
Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds Grant 7,163,703 - Ellison , et al. January 16, 2	2007-01-16
Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds Grant 7,132,116 - Ellison , et al. November 7, 2	2006-11-07
Method for treating cancer App 20060111284 - Yurkow; Edward J. ; et al.	2006-05-25
Compositions and methods for the treatment of Primary and metastatic neoplastic diseases using arsenic compounds App 20050191367 - Ellison, Ralph M. ; et al.	2005-09-01
Controlled release formulations App 20050175679 - Moshman, Michael ; et al.	2005-08-11
Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds App 20050100611 - Ellison, Ralph M. ; et al.	2005-05-12
Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds Grant 6,875,451 - Ellison , et al. April 5, 2	2005-04-05
Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds App 20040197420 - Ellison, Ralph M. ; et al.	2004-10-07
Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds App 20040197421 - Ellison, Ralph M. ; et al.	2004-10-07
NMDA receptor antagonist formulation with reduced neurotoxicity App 20040138298 - Mermelstein, Fred H. ; et al.	2004-07-15
Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds App 20040096518 - Ellison, Ralph M. ; et al.	2004-05-20
NMDA receptor antagonist formulation with reduced neurotoxicity App 20040059003 - Mermelstein, Fred H. ; et al.	2004-03-25
Method for treating cancer App 20030036513 - Yurkow, Edward J. ; et al.	2003-02-20
Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds App 20020183385 - Ellison, Ralph M. ; et al.	2002-12-05

Company Registrations

SEC

0001311357

Mermelstein Fred H

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.